Reality Check on Non-Small Cell Lung Cancer BRAF+
Market access for non-small cell lung cancer BRAF+ treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 71% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In June 2017, the FDA gave full approval to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in people with metastatic nonsmall cell lung cancer with a BRAF V600E mutation as detected by an FDA-approved test. The agency gave the Novartis Pharmaceuticals Corp. drugs breakthrough therapy designation and accelerated approval in July 2015 for this use
- Key Findings: Coverage is under the pharmacy benefit. Prior authorization is required for both Mekinist and Tafinlar to ensure appropriate use. Payer policies for lung cancer typically follow National Comprehensive Cancer Network (NCCN) guidelines
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.